- Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases Learn more about Sarepta
- About Our Company | Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short
- Our Pipeline | Sarepta Therapeutics
Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology
- Investor Relations | Sarepta Therapeutics, Inc.
The Investor Relations website contains information about Sarepta Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
- News Press Releases | Sarepta Therapeutics
Read news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to . . .
Sarepta is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for ELEVIDYS
- Our Disease Areas | Sarepta Therapeutics
At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases Today, our primary focus is on Duchenne muscular dystrophy, limb-girdle muscular dystrophies, and Charcot-Marie-Tooth disease
- Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to . . .
CAMBRIDGE, Mass -- (BUSINESS WIRE)--Jun 20, 2024-- Sarepta Therapeutics, Inc (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced U S Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with
|